证券代码：300584 证券简称：海辰药业 公告编号：2025-013 南京海辰药业股份有限公司 2024 年度内部控制评价报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称企业内部控制规范体系），结合本公司（以下简称公司）内部控制 制度和评价办法，在内部控制日常监督和专项监督的基础上，我们对公司 2024 年 12 月 31 日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准 日，不存在财务报告内部控制重大缺陷，董事会认为，公司已按照企业内部控制 规范体系和相关规定的要求在所有重大方面保持了有效的财务报告内部控制。 根据公司非财务报告内部控制重大缺陷认定情况，于内部控制评价报告基准 日，公司未发现非财务报告内部控制重大缺陷。 自内部控制评价报告基准日至内部控制评价报告发出日之间未发生影响内 部控制有效性评价结论的因素。 三、内部控制评价工作情况 （一）内 ...

证券代码：300584 证券简称：海辰药业 公告编号：2025-012 南京海辰药业股份有限公司 2025 年度财务预算报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据公司战略发展目标及 2025 年度生产经营和发展计划，以经审计的 2024 年度的经营业绩为基础，结合国家和地区宏观经济政策，对公司 2025 年财务预 算报告编制如下： 1、营业收入：预计公司 2025 年度营业收入较上年同期增长 10%-30%； 2、净利润：预计公司 2025 年度扣非后净利润较上年同期增长 10%-30%。 三、具体措施 1、公司坚定致力于科技创新，不断加强研发投入，推进高端品种申报上市， 从而持续推动新产品的迭代更新，以满足市场需求，提升竞争力。 2、国内首仿国谈品种注射用盐酸兰地洛尔及带量采购品种致力于提升终端 覆盖，通过精细化管理以及市场推广力度已取得显著成效，预计 2025 年销量将 一、预算编制的基本假设 1、公司所遵循的国家和地方现行有关法律、法规和制度无重大变化； 2、公司主要经营所在地及业务涉及地区的社会经济环境无重大变化； 3、公司主要产品和原 ...

南京海辰药业股份有限公司 证券代码：300584 证券简称：海辰药业 公告编号：2025-018 董事会审计委员会对年审会计师履行监督职责情况报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司（以下简称"公司"）董事会审计委员会根据《中 华人民共和国公司法》《上市公司治理准则》《国有企业、上市公司选聘会计师事 务所管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》等法律法规、规范性文件以及《公司章程》《董事会审计委员会 工作细则》等规定和要求，本着勤勉尽责的原则，恪尽职守，认真履职。现将董 事会审计委员会对会计师事务所履行监督职责的情况汇报如下： 一、会计师事务所基本信息 （一）机构信息 1、基本信息 名称：天衡会计师事务所（特殊普通合伙） 机构性质：特殊普通合伙企业 成立日期：2013 年 11 月 4 日 统一社会信用代码：913200000831585821 注册地址：江苏省南京市建邺区江东中路 106 号 1907 室 首席合伙人：郭澳 2024 年末合伙人数量：85 人 2024 年末注 ...

| 名称 | 持有数量(万股) | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 曹于平 | 1262.28 | 15.37 | 不变 | | 姜晓群 | 1197.39 | 14.58 | 不变 | | 柳晓泉 | 463.71 | 5.65 | -136.28 | | 西藏信托有限公司-西藏信托-智臻33号集合资金信 | | | | | 托计划 | 108.87 | 1.33 | 不变 | | 严美强 | 102.08 | 1.24 | 不变 | | 曹伟 | 45.69 | 0.56 | 不变 | | 丁腊英 | 40.00 | 0.49 | 不变 | | 蒋金元 | 29.00 | 0.35 | 新进 | | MORGAN STANLEY & CO. INTERNATIONAL | 28.63 | 0.35 | 新进 | | PLC. | | | | | 古秀珠 | 28.61 | 0.35 | 新进 | | 较上个报告期退出前十大股东有 | | | | | Barclays Bank PLC | 61.55 | 0.75 ...

证券代码：300584 证券简称：海辰药业 公告编号：2025-022 南京海辰药业股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》（以下简称"《公司法》"）和《公司章程》的 规定，经南京海辰药业股份有限公司（以下简称"公司"）第四届董事会第二十 次会议审议通过，决定于2025年5月28日（星期三）召开公司2024年度股东大会。 将会议相关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024年度股东大会 2、股东大会的召集人：董事会 3、会议召开的合法、合规性：本次股东大会的召开符合《公司法》《深圳证 券交易所创业板股票上市规则》等有关法律、法规、部门规章、规范性文件及《公 司章程》的规定。 4、会议召开的日期、时间 （1）现场会议召开时间：2025年5月28日（星期三）下午14:00； （2）网络投票时间：2025年5月28日； 其中，通过深圳证券交易所交易系统进行网络投票的时间为：2025年5月28 日（星期三）9:15-9:25、9:30-11:30、13:0 ...

证券代码：300584 证券简称：海辰药业 公告编号：2025-010 南京海辰药业股份有限公司 第四届监事会第十八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由监事会主席罗艳女士召集，会议通知于 2025 年 4 月 8 日通 过电话、电子邮件、专人送达等形式送达至各位监事，监事会会议通知中包括会 议的相关材料，同时列明了会议的召开时间、地点、内容和方式。 2、本次监事会于 2025 年 4 月 18 日在公司会议中心三楼会议室召开，本次 会议采取现场表决的方式召开。 1、审议通过了《2024 年度监事会工作报告》 具体内容详见公司同日披露在中国证监会创业板指定信息披露网站巨潮资 讯网（www.cninfo.com.cn）的《2024 年度监事会工作报告》。 表决结果：同意 3 票，反对 0 票，弃权 0 票，议案获得通过。 本议案尚需提交 2024 年度股东大会审议。 2、审议通过了《2024 年年度报告全文及其摘要》 经审核，监事会认为董事会编制和审核的公司《2024 年年度报告全文》及 《202 ...

证券代码：300584 证券简称：海辰药业 公告编号：2025-009 南京海辰药业股份有限公司 第四届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长曹于平先生召集，会议通知于 2025 年 4 月 8 日电 话、电子邮件、专人送达等形式送达至各位董事，董事会会议通知中包括会议的 相关材料，同时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 4 月 18 日在公司会议中心三楼会议室召开，本次 会议采取现场结合通讯表决方式召开。 3、本次董事会应出席 7 人，实际出席会议人数为 7 人。其中李翔以通讯表 决方式参会。 4、本次董事会由董事长曹于平先生主持，公司部分高级管理人员、证券部 工作人员列席了会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、董事会会议审议情况 会议审议并通过如下议案： 1、审议通过《2024 年度总经理工作报告》 表决结果：同意 7 票，反对 0 票，弃权 0 票，议案获得通 ...

南京海辰药业股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司（以下称"公司"）于 2025 年 4 月 18 日召开第 四届董事会第二十次次会议、第四届监事会第十八次会议，审议通过了《关于 2024 年度利润分配的预案》，该议案尚需提交公司股东大会审议。现将相关事 宜公告如下： 一、利润分配方案的基本情况 证券代码：300584 证券简称：海辰药业 公告编号：2025-014 （一）本次利润分配预案为 2024 年度利润分配。 （二）经天衡会计师事务所（特殊普通合伙）审计，公司 2024 年度合并报表 中实现归属于母公司所有者的净利润 40,217,910.88 元，其中母公司净利润 50,927,064.04 元。截至 2024 年度末，公司合并报表可供股东分配的利润为 630,707,060.37 元，母公司可供股东分配的利润为 703,436,625.36 元。按照合 并报表、母公司报表中可供分配利润孰低的原则，公司 2024 年度可供分配利润 为 630,707,060.37 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 142,649,339.94, representing a 36.43% increase compared to CNY 104,561,855.22 in the same period last year[5] - Net profit attributable to shareholders was CNY 15,036,959.76, up 12.57% from CNY 13,357,813.44 year-on-year[5] - Basic earnings per share rose to CNY 0.1253, reflecting a 12.58% increase from CNY 0.1113 in the same quarter last year[5] - Total operating revenue for the current period reached ¥142,649,339.94, a significant increase of 36.4% compared to ¥104,561,855.22 in the previous period[19] - Net profit for the current period was ¥14,962,869.89, representing a 12.0% increase from ¥13,357,813.44 in the previous period[21] - Earnings per share (EPS) for the current period was ¥0.1253, compared to ¥0.1113 in the previous period, reflecting a growth of 11.4%[21] Cash Flow - The net cash flow from operating activities surged to CNY 43,159,301.39, a remarkable increase of 822.02% compared to CNY 4,680,974.46 in the previous year[5] - Cash generated from operating activities was ¥151,327,782.50, an increase from ¥110,487,507.44 in the previous period[23] - Net cash flow from operating activities was 43,159,301.39, a significant increase from 4,680,974.46 in the previous period, indicating strong operational performance[24] - Cash and cash equivalents at the end of the period reached CNY 51,240,749.34, marking a 157.82% increase from CNY 19,874,244.44 at the end of the previous year[10] - Cash and cash equivalents at the end of the period amounted to 51,240,749.34, up from 19,874,244.44, showing improved liquidity[25] - The company reported a net increase in cash and cash equivalents of 5,482,031.51, contrasting with a decrease of 26,947,843.71 in the previous period[25] Expenses - Sales expenses increased by 46.10% to CNY 56,390,082.47, attributed to enhanced market penetration and increased promotional efforts[9] - The company experienced a 109.87% rise in management expenses, totaling CNY 38,657,009.14, primarily due to increased market research costs[9] - Total operating costs amounted to ¥124,158,918.05, up 45.0% from ¥85,582,384.45 in the prior period[20] - Research and development expenses were ¥4,331,960.14, a decrease from ¥5,429,812.44 in the previous period, indicating a focus on cost management[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,479,220,603.58, a 1.00% increase from CNY 1,464,546,955.74 at the end of the previous year[5] - Current assets total CNY 339,881,407.21, down from CNY 357,153,809.21 at the beginning of the period[16] - The company's fixed assets increased to CNY 239,081,615.92 from CNY 211,895,926.40[16] - The total non-current assets amount to CNY 1,139,339,196.37, up from CNY 1,107,393,146.53[16] - Total liabilities amounted to ¥426,101,674.20, slightly down from ¥426,373,270.65 in the previous period[17] - The company’s total current liabilities were ¥335,985,022.95, slightly up from ¥335,350,592.19 in the previous period[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,335[12] - The largest shareholder, Mr. Cao Yuping, holds 42.08% of the shares, totaling 50,491,306 shares, with 4,000,000 shares pledged[12] - The second-largest shareholder, Ms. Jiang Xiaoqun, holds 9.98% of the shares, totaling 11,973,913 shares[12] - The company has a total of 62,465,219 shares held by the largest and second-largest shareholders combined, representing 52.05% of the total shares[13] - The company has a total of 12,622,827 unrestricted shares held by Mr. Cao Yuping[13] Investment Activities - Net cash flow from investment activities was -35,246,026.30, a decline from -29,319,647.03, indicating higher investment outflows[24] - The company’s total cash inflow from investment activities was 1,005,809.45, reflecting limited investment recovery[24] - The company’s cash outflow for purchasing fixed assets was 27,151,835.75, slightly down from 29,319,647.03, indicating a reduction in capital expenditures[24] Credit and Impairment - The company reported a 597.78% increase in credit impairment losses, amounting to CNY 1,437,594.09, mainly due to the reversal of bad debt provisions[10]

Financial Performance - The company's operating revenue for 2024 was ¥504,360,394.59, a decrease of 2.60% compared to ¥517,832,192.00 in 2023[20] - The net profit attributable to shareholders for 2024 was ¥40,217,910.88, representing an increase of 10.75% from ¥36,315,554.07 in 2023[20] - Basic earnings per share for 2024 were ¥0.3351, up 10.74% from ¥0.3026 in 2023[20] - Total assets at the end of 2024 reached ¥1,464,546,955.74, a 3.95% increase from ¥1,408,864,380.40 at the end of 2023[20] - The net assets attributable to shareholders increased to ¥1,022,936,243.51, reflecting a growth of 3.59% from ¥987,496,138.22 in 2023[20] - The company reported a weighted average return on equity of 4.00% for 2024, up from 3.75% in 2023[20] - The company’s financial expenses increased by 23.57% to ¥9,091,983.54 in 2024 compared to ¥7,357,995.26 in 2023[81] - The total cash outflow from investing activities decreased by 63.70% to ¥79,936,524.65 in 2024 from ¥220,222,058.00 in 2023[86] - The cash and cash equivalents net increase was -¥1,063,370.32 in 2024, a significant improvement from -¥48,246,035.32 in 2023, reflecting a 97.80% change[86] Cash Flow and Expenses - The net cash flow from operating activities significantly improved to ¥59,960,141.82, a 150.54% increase from ¥23,932,692.09 in 2023[20] - The total sales expenses decreased by 16.49% to ¥201,766,882.46 in 2024 from ¥241,595,638.54 in 2023[81] - The company reported a significant reduction in raw material costs, down 18.73% to ¥35,373,670.73 in 2024 from ¥43,526,694.72 in 2023[77] - The company’s depreciation expenses decreased by 9.31% to ¥9,040,625.74 in 2024 from ¥9,968,322.52 in 2023[77] Market and Product Development - The company plans to distribute a cash dividend of ¥1.00 per 10 shares, based on a total of 120,000,000 shares[4] - The company highlighted risks including changes in industry policies and competition in the market for its main product, rivaroxaban tablets[3] - Future outlook includes ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[3] - The company is actively pursuing new product development and market expansion strategies to enhance its competitive position[61] - The company has 8 key projects in the research pipeline, which are expected to enrich its product offerings[62] - The company plans to submit several applications for generic drug registrations, indicating a focus on expanding its market presence[63] Industry Context - The pharmaceutical manufacturing industry in China achieved a revenue of 25,298.5 billion in 2024, remaining stable compared to the previous year, with a profit total of 3,420.7 billion, down 1.1% year-on-year[31] - In 2024, the average price reduction from the national drug procurement program reached 54%, saving over 200 billion in medical insurance funds[33] - The company faced challenges from industry policies but also saw opportunities for growth in innovative drug development and international expansion[34] Research and Development - The company has participated in over 20 national and provincial-level technology projects, enhancing its R&D capabilities[35] - The R&D center has over 60 dedicated personnel and has undertaken more than 20 national and provincial-level technology projects, enhancing the company's innovation capabilities[48] - The company has optimized its research and development pipeline, focusing on high-tech and high-quality drug development[61] Governance and Management - The company has established a governance structure to manage its expanding operations and is focused on improving its management practices to adapt to changing market conditions[116] - The board of directors operates efficiently and adheres to the regulations set forth in the Company Law and Articles of Association[122] - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management[123] - The company has a complete research, production, and sales system, ensuring independence from its controlling shareholders[124] Employee and Training Initiatives - The company conducted a total of 269 company-level training sessions and 458 department-level training sessions during the reporting period, totaling 5888.5 hours of training[159] - The company aims to enhance its performance evaluation system and link assessment results to employee compensation to foster a performance-oriented culture[158] - The company has established a comprehensive employee training system to enhance staff quality and provide more development opportunities, ensuring a harmonious labor relationship[184] Environmental Responsibility - The company has established a dedicated department for environmental protection and energy conservation, ensuring compliance with environmental regulations[187] - The company has implemented a comprehensive emergency response plan for environmental incidents, filed with the local environmental protection bureau[180] - The company has complied with environmental regulations, with wastewater and air emissions meeting national standards[176] Community Engagement - The company has donated a total of 700,000 yuan to support the Hai Chen Hope Primary School, continuing its long-term commitment to social responsibility[188] - The company has actively participated in various community charity events, accumulating donations of 890,000 yuan over the past four years[188]